252 related articles for article (PubMed ID: 25348528)
1. Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes.
Buyck JM; Tulkens PM; Van Bambeke F
Antimicrob Agents Chemother; 2015 Jan; 59(1):258-68. PubMed ID: 25348528
[TBL] [Abstract][Full Text] [Related]
2. Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
Pankuch GA; Lin G; Seifert H; Appelbaum PC
Antimicrob Agents Chemother; 2008 Jan; 52(1):333-6. PubMed ID: 17967915
[TBL] [Abstract][Full Text] [Related]
3. Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of
Mataraci Kara E; Yilmaz M; İstanbullu Tosun A; Özbek Çelik B
Infect Dis (Lond); 2020 Sep; 52(9):616-624. PubMed ID: 32427010
[No Abstract] [Full Text] [Related]
4. Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones.
Montero MM; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Padilla E; Prim N; Segura C; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
J Glob Antimicrob Resist; 2019 Sep; 18():37-44. PubMed ID: 31154007
[TBL] [Abstract][Full Text] [Related]
5. Investigation of synergism of meropenem and ciprofloxacin against Pseudomonas aeruginosa and Acinetobacter strains isolated from intensive care unit infections.
Ermertcan S; Hoşgör M; Tünger O; Coşar G
Scand J Infect Dis; 2001; 33(11):818-21. PubMed ID: 11760161
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
[TBL] [Abstract][Full Text] [Related]
7. Bacteriophage-antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa: In vitro synergy testing.
Holger DJ; Lev KL; Kebriaei R; Morrisette T; Shah R; Alexander J; Lehman SM; Rybak MJ
J Appl Microbiol; 2022 Sep; 133(3):1636-1649. PubMed ID: 35652690
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of sub-MIC level of meropenem and ciprofloxacin against extensive drug-resistant (XDR) Pseudomonas aeruginosa isolates of diabetic foot ulcer patients.
Srivastava P; Sivashanmugam K
Infect Genet Evol; 2021 Aug; 92():104824. PubMed ID: 33774177
[TBL] [Abstract][Full Text] [Related]
9. Determination of synergy by two methods with eight antimicrobial combinations against tobramycin-susceptible and tobramycin-resistant strains of Pseudomonas.
Chan EL; Zabransky RJ
Diagn Microbiol Infect Dis; 1987 Feb; 6(2):157-64. PubMed ID: 3102156
[TBL] [Abstract][Full Text] [Related]
10. Structural changes and differentially expressed genes in Pseudomonas aeruginosa exposed to meropenem-ciprofloxacin combination.
Siqueira VL; Cardoso RF; Caleffi-Ferracioli KR; Scodro RB; Fernandez MA; Fiorini A; Ueda-Nakamura T; Dias-Filho BP; Nakamura CV
Antimicrob Agents Chemother; 2014 Jul; 58(7):3957-67. PubMed ID: 24798291
[TBL] [Abstract][Full Text] [Related]
11. Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.
Rees VE; Yadav R; Rogers KE; Bulitta JB; Wirth V; Oliver A; Boyce JD; Peleg AY; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104278
[TBL] [Abstract][Full Text] [Related]
12. The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
Erdem I; Kaynar-Tascioglu J; Kaya B; Goktas P
Int J Antimicrob Agents; 2002 Nov; 20(5):384-6. PubMed ID: 12431875
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments.
Tängdén T; Hickman RA; Forsberg P; Lagerbäck P; Giske CG; Cars O
Antimicrob Agents Chemother; 2014; 58(3):1757-62. PubMed ID: 24395223
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
Erdem I; Kucukercan M; Ceran N
Chemotherapy; 2003 Dec; 49(6):294-7. PubMed ID: 14671429
[TBL] [Abstract][Full Text] [Related]
15. Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model.
Mohamed AF; Kristoffersson AN; Karvanen M; Nielsen EI; Cars O; Friberg LE
J Antimicrob Chemother; 2016 May; 71(5):1279-90. PubMed ID: 26850719
[TBL] [Abstract][Full Text] [Related]
16. Activity of Antibiotics against Pseudomonas aeruginosa in an
Diaz Iglesias Y; Van Bambeke F
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015047
[No Abstract] [Full Text] [Related]
17. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
[TBL] [Abstract][Full Text] [Related]
18.
Goodlet KJ; Nicolau DP; Nailor MD
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
[TBL] [Abstract][Full Text] [Related]
19. Combining antibiotics with antivirulence compounds can have synergistic effects and reverse selection for antibiotic resistance in Pseudomonas aeruginosa.
Rezzoagli C; Archetti M; Mignot I; Baumgartner M; Kümmerli R
PLoS Biol; 2020 Aug; 18(8):e3000805. PubMed ID: 32810152
[TBL] [Abstract][Full Text] [Related]
20. Effect of combined colistin and meropenem against meropenem resistant
Gunalan A; Sarumathi D; Sastry AS; Ramanathan V; Rajaa S; Sistla S
Indian J Pharmacol; 2021; 53(3):207-212. PubMed ID: 34169905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
